Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

It was there that Mr Pearce, 40, was diagnosed with a branch retinal vein occlusion, where one of the veins in the retina ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

While all large and medium vessel occlusions (up to middle cerebral artery M2 segment) are documented in the GSR, we cannot exclude the possibility that some of the patients with ICA-I and ICA-E had ...

Most patients (84.7%) had primary occlusions in a middle-cerebral-artery branch. A modified Rankin scale score of 0 or 1 at 90 days occurred in 106 of 255 patients (41.6%) in the EVT group and in ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Front Line Medical Technologies Inc. COBRA-OS REBOA (large vessel balloon occlusion device; 4-F; 25-mm diameter-balloon; guidewire-free) Distal Intended for temporary occlusion of large vessels ...

The antiphospholipid syndrome associated with hepatic vein thrombosis has usually been of the primary type; that is, the American Rheumatism Association criteria for the diagnosis of systemic ...

CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...